How can inhibition of glucose and sodium transport in the early proximal tubule protect the cardiorenal system?
V Vallon - Nephrology Dialysis Transplantation, 2024 - academic.oup.com
What mechanisms can link the inhibition of sodium-glucose cotransporter 2 (SGLT2) in the
early proximal tubule to kidney and heart protection in patients with and without type 2 …
early proximal tubule to kidney and heart protection in patients with and without type 2 …
Animal models to study cognitive impairment of chronic kidney disease
PH Imenez Silva, M Pepin, A Figurek… - American Journal …, 2024 - journals.physiology.org
Mild cognitive impairment (MCI) is common in people with chronic kidney disease (CKD),
and its prevalence increases with progressive loss of kidney function. MCI is characterized …
and its prevalence increases with progressive loss of kidney function. MCI is characterized …
SGLT2-independent effects of canagliflozin on NHE3 and mitochondrial complex I activity inhibit proximal tubule fluid transport and albumin uptake
WN Albalawy, EB Youm, KE Shipman… - American Journal …, 2024 - journals.physiology.org
Beyond glycemic control, SGLT2 inhibitors (SGLT2i) have protective effects on cardiorenal
function. Renoprotection has been suggested to involve inhibition of NHE3 leading to …
function. Renoprotection has been suggested to involve inhibition of NHE3 leading to …
[HTML][HTML] Transient inhibition of sodium-glucose cotransporter 2 after ischemia/reperfusion injury ameliorates chronic kidney disease
MÁ Martínez-Rojas, H Balcázar, I González-Soria… - JCI insight, 2024 - ncbi.nlm.nih.gov
Abstract Sodium-glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin (Dapa), exhibited
nephroprotective effects in patients with chronic kidney disease (CKD). We assessed the …
nephroprotective effects in patients with chronic kidney disease (CKD). We assessed the …
Key results from observational studies and real‐world evidence of sodium‐glucose cotransporter‐2 inhibitor effectiveness and safety in reducing cardio‐renal risk
T Nyström - Diabetes, Obesity and Metabolism, 2024 - Wiley Online Library
Abstract Sodium‐glucose cotransporter 2 (SGLT2) inhibitors, originally designed to manage
blood sugar levels in individuals with type 2 diabetes (T2D), have emerged as a crucial …
blood sugar levels in individuals with type 2 diabetes (T2D), have emerged as a crucial …
[HTML][HTML] Indoxyl Sulfate-Induced Macrophage Toxicity and Therapeutic Strategies in Uremic Atherosclerosis
T Wakamatsu, S Yamamoto, S Yoshida, I Narita - Toxins, 2024 - mdpi.com
Cardiovascular disease (CVD) frequently occurs in patients with chronic kidney disease
(CKD), particularly those undergoing dialysis. The mechanisms behind this may be related …
(CKD), particularly those undergoing dialysis. The mechanisms behind this may be related …
Nascent shifts in renal cellular metabolism, structure, and function due to chronic empagliflozin in prediabetic mice
BD Shepard, J Chau, R Kurtz… - … of Physiology-Cell …, 2024 - journals.physiology.org
Sodium-glucose cotransporter, type 2 inhibitors (SGLT2i) are emerging as the gold standard
for treatment of type 2 diabetes (T2D) with renal protective benefits independent of glucose …
for treatment of type 2 diabetes (T2D) with renal protective benefits independent of glucose …
Blood-based cardiometabolic phenotypes in atrial fibrillation and their associated risk: EAST-AFNET 4 biomolecule study
Aims Atrial fibrillation (AF) and concomitant cardiometabolic disease processes interact and
combine to lead to adverse events, such as stroke, heart failure, myocardial infarction, and …
combine to lead to adverse events, such as stroke, heart failure, myocardial infarction, and …
Renal upregulation of NCC counteracts empagliflozin-mediated NHE3 inhibition in normotensive but not in hypertensive male rat
PC Castro, TM Santos-Rios… - … of Physiology-Cell …, 2024 - journals.physiology.org
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce blood pressure (BP) in patients
with hypertension, yet the precise molecular mechanisms remain elusive. SGLT2i inhibits …
with hypertension, yet the precise molecular mechanisms remain elusive. SGLT2i inhibits …
[HTML][HTML] Dapagliflozin and atrial fibrillation: elevated dosing to achieve class I antiarrhythmic effects?
T Christ, E Schwedhelm, T Eschenhagen - Basic Research in Cardiology, 2024 - Springer
Inhibitors of sodium–glucose co-transporter-2 (SGLT2i) robustly decrease morbidity and
mortality in patients with heart failure and chronic kidney disease, both in diabetic and non …
mortality in patients with heart failure and chronic kidney disease, both in diabetic and non …